Cormorant Asset Management, LP - 31 Dec 2025 SCHEDULE 13G Report for MoonLake Immunotherapeutics Class A ordinary share, par value $0.0001 per share (MLTX)

Filing Manager
Cormorant Asset Management, LP
Reporting Manager
Cormorant Asset Management, LP
Security
MoonLake Immunotherapeutics Class A ordinary share, par value $0.0001 per share
Symbol
MLTX
Shares outstanding
71,400,541 shares
Disclosed Ownership
4,355,433 shares
Ownership
6.1%
Form type
SCHEDULE 13G
Filing time
17 Feb 2026, 15:01:28 UTC
Date of event
31 Dec 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Cormorant Asset Management, LP disclosed 6.1% ownership in MoonLake Immunotherapeutics Class A ordinary share, par value $0.0001 per share (MLTX) on 31 Dec 2025."

Quick Takeaways

  • Cormorant Asset Management, LP filed SCHEDULE 13G for MoonLake Immunotherapeutics Class A ordinary share, par value $0.0001 per share (MLTX).
  • Disclosed ownership: 6.1%.
  • Date of event: 31 Dec 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 17 Feb 2026, 15:01.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (2)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Cormorant Asset Management, LP 6.1% 4,355,433 0 4,355,433 /s/ Bihua Chen Bihua Chen, Managing Member
Bihua Chen 6.1% 4,355,433 0 4,355,433 /s/ Bihua Chen Bihua Chen

Sponsored